How Continuous Safety Monitoring Can Reduce Hospital Stays for High-Risk Oncology Patients

Cellular therapy products such as CAR-T show promising clinical efficacy in fighting cancer. But the accompanying risk of fast-onset cytokine release syndrome (CRS) has driven a standard of care that includes lengthy hospital stays following infusion. Long hospital stays—often 2 weeks—present a high risk for infection along with a high financial and emotional burden for patients and families, and ultimately drive-up costs and reduce the accessibility of these therapies.

In this webinar, we discuss recent research at Mount Sinai evaluating the feasibility of dramatically reducing hospital stays for patients undergoing CAR-T therapy through the use of continuous safety monitoring in the Current Health platform.
Study leaders will:

1. Discuss the context of CAR-T therapy and the business case for outpatient experiences.
2. Present and analyze the research study results.
3. Share insights into the patient experience.
4. Explore implications for the future of oncology care.

Speakers

• Sridevi Rajeeve, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
• Nicole Zahradka, PhD, Sr. Clinical Research Program Manager, Current Health